Uncover key drivers, emerging technologies, and competitive movements shaping the arthritis monoclonal antibodies market from 2026–2035 with trusted insights from The Business Research Company
How much larger will the Arthritis Monoclonal Antibodies Market be in 2030 compared with 2026?
The arthritis monoclonal antibodies market size has experienced strong growth in recent years. It is projected to expand from $66.45 billion in 2025 to $71.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. This historical growth can be attributed to several factors including the increasing prevalence of rheumatoid arthritis, the limited effectiveness of conventional dmards, growing awareness of biologic therapies, the expansion of hospital-based rheumatology care, and rising healthcare expenditure.
The arthritis monoclonal antibodies market size is anticipated to undergo significant expansion in the coming years. This sector is projected to reach $98.46 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.3%. The expected growth during the forecast period is primarily driven by factors such as the advancement of next-generation monoclonal antibodies, an increase in the introduction of biosimilars, the development of personalized immunotherapy approaches, a rising elderly population affected by arthritis conditions, and improvements in reimbursement policies for biologics. Prominent trends throughout this period include the increasing adoption of biologic therapies for autoimmune arthritis, a growing preference for targeted monoclonal antibody treatments, the rise of early and aggressive treatment strategies, the wider availability of biosimilars for arthritis monoclonal antibodies, and improved patient access facilitated by hospital and specialty clinics.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp
What Drivers Are Guiding Growth Patterns In The Arthritis Monoclonal Antibodies Market?
The arthritis monoclonal antibody market is projected to be propelled by the increasing approvals for personalized medicines. Personalized medicines are defined as therapeutic products or treatments specifically designed for individual patients. Their design is based on a patient’s genetic, biomarker, phenotypic, or psychosocial characteristics, which can predict their response to a particular treatment. Monoclonal antibodies (mABs) represent the latest generation of drugs that align with the personalized medicine paradigm, potentially improving patient outcomes and healthcare efficiency. For instance, in February 2024, a report by the Personalized Medicine Coalition, a US-based non-profit organization promoting personalized medicine adoption, examined the importance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 significant new or expanded indications for 12 diagnostic testing products. Therefore, the rising approvals of personalized medicines are driving the arthritis monoclonal antibody market.
Which Segments Are Driving Activity In The Arthritis Monoclonal Antibodies Market?
The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users
What Long-Term Trends Are Expected To Shape The Future Of The Arthritis Monoclonal Antibodies Market?
Leading companies active in the arthritis monoclonal antibody market are introducing novel biosimilar versions, such as Hulio, to provide more accessible treatment. Hulio serves as a biosimilar counterpart to Humira, AbbVie’s prominent rheumatoid arthritis drug. For instance, in July 2023, Biocon Biologics, an India-based subsidiary of Biocon Limited specializing in biosimilar therapies, launched Hulio (adalimumab-fkjp), a biosimilar version of Humira. This particular monoclonal antibody, utilized for conditions like rheumatoid arthritis and psoriatic arthritis, is priced 5% lower than Humira, which is presently listed at $6,922 per carton.
Which Major Industry Participants Are Leading The Arthritis Monoclonal Antibodies Market Growth?
Major companies operating in the arthritis monoclonal antibodies market are Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Is Expected To Experience The Fastest Growth In The Arthritis Monoclonal Antibodies Market?
North America was the largest region in the arthritis monoclonal antibodies market in 2025. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Arthritis Monoclonal Antibodies Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3449&type=smp
Browse Through More Reports Similar to the Global Arthritis Monoclonal Antibodies Market 2026, By The Business Research Company
Musculoskeletal Disorder Drugs Market Report 2026
Microbiome Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report
Orthobiologics Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model